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Introduction: Allergic Rhinitis (AR) is a chronic, symptomatic allergic disorder of the nose that is 
usually caused by IgE-mediated inflammatory response following exposure to an allergen. The 
allergen could be in the form of dust, pollen, flower, animal dander, mold, cold, food allergens or 
insect. Clinically, AR occurs when there are recurrent nasal symptoms which are reversible either 
spontaneously or with medication in the preceding one year. Such symptoms include at least two 












of the following; excessive sneezing, running nose, nasal itching, nasal discharge, nasal 
congestion or obstruction. 
Previous studies have linked AR to be co-existed with another form of allergic disorders including 
AC, Atopic dermatitis and Allergic Asthma. 
This study is aimed at assessing the feature of  AR patients with coexistent AC as well as 
evaluating the effectiveness of the treatments offered to them.  
Objectives: The study was aimed at finding the correlation between the nasal and eye features in 
a patient who has co-existing allergic rhinitis and allergic conjunctivitis. 
Methodology: This was a cross-sectional descriptive study conducted between August 2018 and 
November 2019 among 38 patients who presented to ENT and Ophthalmology departments of 
Federal Teaching Hospital Ido-Ekiti, Ekiti State, Southwestern Nigeria and was diagnosed with 
both allergic rhinitis and allergic conjunctivitis. Relevant data obtained were analyzed using SPSS 
version 20.  P ≤ 0.05 was taken as significant. 
Results: The patients’ age range between 8 and 81 years with a median age of 33 years. The 
majority were less than 45 years (63.2%) with the male to female ratio of almost. Eye pain, itching, 
and redness account for 97.4% of all the eye features, while the presence of Cobblestone-like 
papillae is the least and accounted for 5%. Nasal itching (92.1%) was the commonest nasal 
symptom. Sleep disturbance was found to be the most common among those with eye itching 
(29.7%). 
Conclusion: This research was conducted to correlate the features of allergic rhinitis with those of 
conjunctivitis and common management and preventive measures offered to the patients seen in 
our clinics. The majority of the patients were less than 45 years with almost equal sex ratio. Eye 
pain, itching, and redness account for the majority of all the eye features, while the presence of 
Cobblestone-like papillae is the least eye feature. Nasal itching was the commonest nasal 
symptom and this was seen in the majority of the patients with eye symptoms.  
 
 




Allergic Rhinitis (AR) is a chronic, symptomatic 
allergic disorder of the nose that is caused by 
IgE-mediated inflammatory response following 
exposure to an allergen. [1] The allergen could 
be in form of dust, pollen, flower, animal dander, 
mold, cold or insect. [2] Clinically, Allergic rhinitis 
occurs when there are recurrent nasal symptoms 
which are reversible either spontaneously or with 
medication in the preceding one year. [3] Such 
symptoms include at least two of the following; 
excessive sneezing, running nose, nasal itching, 
nasal discharge, nasal congestion or obstruction. 
[3]. 
 
The aim of this study was to determine the 
correlation between clinical features of Allergic 
Rhinitis (AR) with Allergic conjunctivitis (AC). The 
availability of such data will be necessary, not 
only for epidemiological purposes but also for 





This is cross-sectional descriptive study was 
conducted between August 2018 and November 
2019 among 38 patients who presented to ENT 
and Ophthalmology departments of Federal 
Teaching Hospital Ido-Ekiti, Ekiti State, 
Southwestern Nigeria and were diagnosed with 
both allergic rhinitis and allergic conjunctivitis. 
Sample size was obtained using G*Power 
version 3.1.9 software to calculate the power 
analysis and determine the optimal sample size. 
The type of power analysis chosen within 
G*Power is “a priori: computer required sample 
size – given α, power, and effect size” and the 
test family chosen was Chi square tests.  The 
statistical test chosen was Goodness of fit tests: 
contingency tables. The effect size identified was 
0.5 (large effect size), the alpha level was 0.05 
while the power level was 0.80. The total sample 
size calculated was 32 however all 38 patients 
that presented to ENT and Ophthalmology with 
both allergic rhinitis and allergic conjunctivitis 
between August 2018 and November 2018 were 
enrolled into the study. Relevant history was 
taken and clinical examinations were carried out 
on the patients. Adequate treatment was offered 
and each patient was followed up for 3 months to 
evaluate the response to the treatment given. 
The data collected from the patients were 
entered into the computer software and analyzed 














The patients’ age range between 8 and 81 years 
with a median age of 33 years. The majority were 
less than 45 years (63.2%) with the male to 
female ratio of almost 1:1 (Table 1). Eye pain, 
itching, and redness account for 97.4% of all the 
eye features (Table 2), while the presence of 
cobblestone-like papillae was the least and 
accounted for 5%. Nasal itching (92.1%) was the 
commonest nasal symptom (Table 3) while the 
least nasal presentations were nasal polyps 
(18.4%) and sleep disturbance (28.9%). Only 
about one-tenth of the patients had used    
allergen immunotherapy while  all  of  them  had  
used  an antihistamine (Table 3). Sleep 
disturbance(Tables 5a & 5b) was found to be     
the most common among those with eye itching 
(29.7%), blurring of vision (31.8%) and those      
on a steroid (37.5%).All the patients             
(100%) benefitted from anti-histamine 
treatment(Table3&6),steroid in 28.9%              
and allergen immunotherapy treatment in  10.5%. 
 
Table 1. Demographic variables 
 
Variable Frequency Percent (%) 
Age group   
< 45 24 63.2 
≥ 45 14 36.8 
Mean ± SD 39.53 ± 22.55 
Median (IQR) 33.00 (19.00 – 59.75) 
Sex   
Male 20 52.6 
Female 18 47.4 
 
Table 2. Eye features and treatment options 
offered 
 
Variable Yes No 
n (%) n (%) 
Symptoms    
Cobblestone-like 
papillae 
5 (13.2) 33 (86.8) 
 Blurring of vision  22 (57.9) 16 (42.1) 
 Eye tearing  32 (84.2) 6 (15.8) 
 Eye discharge  35 (92.1) 3 (7.9) 
 Hyperemia  36 (94.7) 2 (5.3) 
 Eye redness  37 (97.4) 1 (2.6) 
 Eye itching  37 (97.4) 1 (2.6) 
 Eye pain  37 (97.4) 1 (2.6) 
Treatment   
 Mast cell stabilizer  7 (18.4) 31 (81.6) 
 Steroid  8 (21.1) 30 (78.9) 
 VCT  20 (52.6) 18 (47.4) 
Table 3. Nasal features and treatment options 
offered 
 
Variable Yes No 
n (%) n (%) 
Symptoms    
 Nasal polyp 7 (18.4) 31 (81.6) 
 Sleep disturbance 11 (28.9) 27 (71.1) 
 Post nasal drip 16 (42.1) 22 (57.9) 
 Impairment of daily 
activities 
18 (47.4) 20 (52.6) 
 Nasal blockage 24 (63.2) 14 (36.8) 
 Hawking 29 (76.3) 9 (23.7) 
 Excoriation of 
external nares 
31 (81.6) 7 (18.4) 
 Pale mucosa / grey 
mucosa 
31 (81.6) 7 (18.4) 
 Nasal discharge 32 (84.7) 6 (15.8) 
 Sneezing  33 (86.8) 5 (13.2) 
Engorged inferior 
turbinate 
34 (89.5) 4 (10.5) 
Nasal itching 35 (92.1) 3 (7.9) 
Treatment    
 Allergen 
immunotherapy 
4 (10.5) 34 (89.5) 
 Environmental control 8 (21.1) 30 (78.9) 
 Steroid 11 (28.9) 27 (71.1) 
 Anti-histamine 38 (100.0) 0 (0.0) 
 
Table 5 shows the correlations of the eye and 





Previous studies have linked Allergic Rhinitis (AR) 
to be co-existed with another form of allergic 
disorders including Allergic Conjunctivitis (AC), 
Atopic dermatitis and Allergic Asthma. [4, 5, 6]
 
 
Allergic conjunctivitis (AC) is an acute or chronic 
inflammatory disorder of the conjunctiva and 
other ocular surfaces that are usually caused by 




The age of the patients seen in our study ranged 
between 8 and 81 years with a median age of 33 
years. Most of them were less than 45 years 
(63.2%) while the male to female ratio was 
almost 1:1 (Table 1). This showed that there was 
no gender predilection to allergic rhinitis nor 
allergic conjunctivitis. 
 
The usual presentation of AC includes bilateral 
intense itching, lacrimation, redness, swollen 











These are similar to what was found in our 
patients. The eye features and the treatment 
offered to our patients are highlighted in Table 1. 
The most prevalent eye symptoms were the pain, 
itching, and redness (97.4%) while coble stone 
was the least common presentation (13.2%) and 
about half of the patients were treated with VCT 
(52.6%). The commonest nasal symptom was 
nasal itching (92.1%) while the least 
presentations were nasal polyp (18.4%) and 
sleep disturbance (28.9%). Only about one-tenth 
of the patients had allergen immunotherapy while 
all of them had antihistamine (Table 3).   
 
AC when co-existed with AR and allergic is 
referred to as Allergic Rhinoconjunctivitis. [6,8] 
An allergic Rhinitis and allergic conjunctivitis 
disorder follow a pattern of seasonal and 
perennial forms, although, the pattern of nasal 
symptoms is mostly of perennial type with a peak 
incidence during the dry season while the pattern 
of ocular symptoms is mostly of seasonal type 
with a peak incidence during the rainy season. 
[9,10]  
 
Correlating the nasal and eye features of our 
patients revealed that Eye itching was found to 
be higher among those with nasal blockage, 
sleep disturbance, post nasal drip, and nasal 
polyps(Table 6). This category of the patients 
benefited from treatment with steroid, allergen 
immunotherapy as well as environmental control. 
Also, eye pain was observed to be more among 
those with nasal discharge, hawking, excoriation 
of external nares, post nasal drip, nasal polyps, 
steroid use, and allergen immunotherapy. 
Similarly, eye redness was found to be higher 
among those with nasal discharge, hawking, 
excoriation of external nares, post nasal drip, 
nasal polyps, steroid use, and allergen 
immunotherapy. The proportion of patients with 
eye tearing was found to be higher among 
patients with nasal discharge, impaired activities 
of daily living, hawking and pale/ grey mucosa. 
As shown in the table, there was no significant 
association between the major eye symptoms 
and nasal features (Table 4a and 4b). 
 
The cause of AR and AC and other forms of 
allergens is an interaction between genetic 
factors (Race, allergic predisposition, family 
history) and environmental factors (Allergens, air 
pollution, diet, water and exposure to cigarette 
smoke). [11] AR and AC are diseases of 
childhood, adolescence and young adult 
irrespective of races, though, can occur at any 
age. [2] Before puberty, more boys than girls are 
affected but after puberty, there is no gender bias. 
[12, 13] 
 
In Tables 4a and 4b, sleep disturbance was 
found to be common among those with eye 
itching (29.7%), blurring of vision (31.8%) and 
those on a steroid (37.5%). Also, a greater 
proportion of patients with the blurring of vision 
(90.9%) and hyperemia (88.9%) had sneezing 
while nasal itching was found to be higher among 
those with a blurring of vision, eye discharge, 
cobblestones, corneal abrasion and those on 
mast cell stabilizer as well as those on steroids. 
Furthermore, patients with eye redness, eye 
tearing, blurring of vision, eye discharge, eye 
pain hyperemia, and those on VCT were shown 
to have a higher prevalence of nasal discharge 
(Table 6). Overall, major nasal symptoms were 
not found to be statistically associated with eye 
symptoms. 
 
AR and AC and other forms of allergies have 
impacted heavy social and economic burdens on 
the general population, causing a reduction in the 
quality of life of the affected people, especially 
during the acute episode. [14,15] According to a 
study by Olajide and colleagues from Ido-Ekiti, 
commonly affected quality of life among children 
are irritability, absenteeism, sleep disruption and 
impaired social life. [15] 
 
The disorder of AR and AC are said to be 
common among the teenagers of high social 
economic class and those living in an industrial 
and urban area. [16] AR has a close 






These disorders are common in the population 
and many studies have observed the increasing 
prevalence of them in many countries. 
 
The epidemiology of ocular allergy in an adult 
population was explored in the National Health 
and Nutritional Examination survey III. [5]
 
The 
survey found 6.4% reported ocular symptoms, 
16.5% nasal symptoms and 29.7%both.
 
[5] 
However, Michael R. Perkin et.al found the 
prevalence of AC as 17.5%, AR15.1%, and 
Rhino-conjunctivitis 13.4% [4]. Oladimeji S.M. 
and colleagues found the prevalence of AC as 
26.0% and AR 40.6% [9]. In a study by Uche 
Okonkwo KC and colleagues, the Prevalence of 
Allergic rhinitis was 56.7% of which                 
28.8% had allergic conjunctivitis. [1]       












Table 4A. Correlating major eye symptoms with the nasal features 
 
Variable Eye itching Eye pain Eye redness Eye tearing 
 Yes No  p value  Yes No p value  Yes No  p value Yes No  p value 
 n (%) n (%)  n (%) n (%)  n (%) n (%)  n (%) n (%)  
Sneezing             
 Yes 32 (97.0) 1 (3.0) 0.269 32 (97.0) 1 (3.0) 0.269 32 (97.0) 1 (3.0) 0.269 27 (81.8) 6 (18.2) 0.703 
 No 5 (100.0) 0 (0.0)  5 (100.0) 0 (0.0)  5 (100.0) 0 (0.0)  5 (100.0) 0 (0.0)  
Nasal discharge             
 Yes 31 (96.9) 1 (3.1) 0.341 32 (100.0) 0 (0.0) 0.341 32 (100.0) 0 (0.0) 0.341 27 (84.4) 5 (15.6) 0.585 
 No 6 (100.0) 0 (0.0)  5 (83.3) 1 (16.7)  5 (83.3) 1 (16.7)  5 (83.3) 1 (16.7)  
Nasal itching             
 Yes 34 (97.1) 1 (2.9) 0.113 34 (97.1) 1 (2.9) 0.113 34 (97.1) 1 (2.9) 0.113 29 (82.9) 6 (17.1) 0.964 
 No 3 (100.0) 0 (0.0)  3 (100.0) 0 (0.0)  3 (100.0) 0 (0.0)  3 (100.0) 0 (0.0)  
Nasal blockage             
 Yes 24 (100.0) 0 (0.0) 0.782 23 (95.8) 1 (4.2) 0.782 23 (95.8) 1 (4.2) 0.782 20 (83.3) 4 (16.7) 0.789 
 No 13 (92.9) 1 (7.1)  14 (100.0) 0 (0.0)  14 (100.0) 0 (0.0)  12 (85.7) 2 (14.3)  
Sleep disturbance             
 Yes 11 (100.0) 0 (0.0) 0.638 10 (90.9) 1 (9.1) 0.638 10 (90.9) 1 (9.1) 0.638 9 (81.8) 2 (18.2) 0.816 
 No 26 (96.3) 1 (3.7)  27 (100.0) 0 (0.0)  27 (100.0) 0 (0.0)  23 (85.2) 4 (14.8)  
Impairment of daily 
activities 
            
 Yes 17 (94.4) 1 (5.6) 0.956 17 (94.4) 1 (5.6) 0.956 17 (94.4) 1 (5.6) 0.956 16 (88.9) 2 (11.1) 0.760 
 No 20 (100.0) 0 (0.0)  20 (100.0) 0 (0.0)  20 (100.0) 0 (0.0)  16 (80.0) 4 (20.0)  
Hawking             
 Yes 28 (96.6) 1 (3.4) 0.530 29 (100.0) 0 (0.0) 0.530 29 (100.0) 0 (0.0) 0.530 25 (86.2) 4 (13.8) 0.709 
 No 9 (100.0) 0 (0.0)  8 (88.9) 1 (11.1)  8 (88.9) 1 (11.1)  7 (77.8) 2 (22.2)  
Excoriation of 
external nares 
            
 Yes 30 (96.8) 1 (3.2) 0.408 31 (100.0) 0 (0.0) 0.408 31 (100.0) 0 (0.0) 0.408 25 (80.6) 6 (19.4) 0.487 
 No 7 (100.0) 0 (0.0)  6 (85.7) 1 (14.3)  6 (85.7) 1 (14.3)  7 (100.0) 0 (0.0)  














Table 4B. Correlating major eye symptoms with the nasal features 
 
 Eye itching Eye pain Eye redness Eye tearing 
 Yes No  p value  Yes No p value  Yes No  p value Yes No  p value 
Variable  n (%) n (%)  n (%) n (%)  n (%) n (%)  n (%) n (%)  
Pale/ grey mucosa             
 Yes 30(96.8) 1(3.2) 0.408 30(96.8) 1(3.2) 0.408 30(96.8) 1(3.2) 0.408 27(87.1) 4(12.9) 0.650 
 No 7(100.0) 0(0.0)  7(100.0) 0(0.0)  7(100.0) 0(0.0)  5(71.4) 2(28.6)  
Engorged inferior 
turbinate 
            
 Yes 33(97.1) 1(2.9) 0.192 33(97.1) 1(2.9) 0.192 33(97.1) 1(2.9) 0.192 28(82.4) 6(17.6) 0.849 
 No 4(100.0) 0(0.0)  4(100.0) 0(0.0)  4(100.0) 0(0.0)  4(100.0) 0(0.0)  
Post nasal drip             
 Yes 16(100.0) 0(0.0) 0.871 16(100.0) 0(0.0) 0.871 16(100.0) 0(0.0) 0.871 13(81.3) 3(18.8) 0.974 
 No 21(95.5) 1(4.5)  21(95.5) 1(4.5)  21(95.5) 1(4.5)  19(86.4) 3(13.6)  
Nasal polyp             
 Yes 7(100.0) 0(0.0) 0.408 7(100.0) 0(0.0) 0.408 7(100.0) 0(0.0) 0.408 5(71.4) 2(28.6) 0.650 
 No 30(96.8) 1(3.2)  30(96.8) 1(3.2)  30(96.8) 1(3.2)  27(87.1) 4(12.9)  
Anti-histamine             
 Yes 37(97.4) 1(2.6)  37(97.4) 1(2.6)  37(97.4) 1(2.6)  32(84.2) 6(15.8)  
Steroid             
 Yes 11(100.0) 0(0.0) 0.638 11(100.0) 0(0.0) 0.638 11(100.0) 0(0.0) 0.638 7(63.6) 4(36.4) 0.083 
 No 26(96.3) 1(3.7)  26(96.3) 1(3.7)  26(96.3) 1(3.7)  25(92.6) 2(7.4)  
Allergen 
immunotherapy 
            
 Yes 4(100.0) 0(0.0) 0.192 4(100.0) 0(0.0) 0.192 4(100.0) 0(0.0) 0.192 2(50.0) 2(50.0) 0.208 
 No 33(97.1) 1(2.9)  33(97.1) 1(2.9)  33(97.1) 1(2.9)  30(88.2) 4(11.8)  
Environmental control             
 Yes 8(100.0) 0(0.0) 0.471 7(87.5) 1(12.5) 0.471 7(87.5) 1(12.5) 0.471 5(62.5) 3(37.5) 0.177 
 No 29(96.7) 1(3.3)  30(100.0) 0(0.0)  30(100.0) 0(0.0)  27(90.0) 3(10.0)  
Asthma             
 Yes 9(100.0) 0(0.0) 0.530 8(88.9) 1(11.1) 0.530 8(88.9) 1(11.1) 0.530 6(66.7) 3(33.3) 0.258 
 No 28(96.6) 1(3.4)  29(100.0) 0(0.0)  29(100.0) 0(0.0)  26(89.7) 3(10.3)  












Table 5A. Correlating major nasal symptoms with the eye symptoms 
 
 Sleep disturbance Sneezing Nasal itching Nasal discharge 
 Yes No  p value  Yes No p value  Yes No  p value Yes No  p value 
Variable  n (%) n (%)  n (%) n (%)  n (%) n (%)  n (%) n (%)  
Eye redness             
 Yes 10(27.0) 27(73.0) 0.638 32(86.5) 5(13.5) 0.269 34(91.9) 3(8.1) 0.114 32(86.5) 5(13.5) 0.342 
 No 1(100.0) 0(0.0)  1(100.0) 0(0.0)  1(100.0) 0(0.0)  0(0.0) 1(100.0)  
Eye itching             
 Yes 11(29.7) 26(70.3) 0.638 32(86.5) 5(13.5) 0.269 34(91.9) 3(8.1) 0.114 31(83.8) 6(16.2) 0.341 
 No 0(0.0) 1(100.0)  1(100.0) 0(0.0)  1(100.0) 0(0.0)  1(100.0) 0(0.0)  
Eye tearing             
 Yes 9(28.1) 23(71.9) 0.816 27(84.4) 5(15.6) 0.703 29(90.6) 3(9.4) 0.964 27(84.4) 5(15.6) 0.585 
 No 2(33.3) 4(66.7)  6(100.0) 0(0.0)  6(100.0) 0(0.0)  5(83.3) 1(16.7)  
Blurring of vision             
 Yes 7(31.8) 15(68.2) 0.924 20(90.9) 2(9.1) 0.701 21(95.5) 1(4.5)  19(86.4) 3(13.6) 0.975 
 No 4(25.0) 12(75.0)  13(81.3) 3(18.8)  14(87.5) 2(12.5) 0.773 13(81.3) 3(18.8)  
Eye pain             
 Yes 10(27.0) 27(73.0) 0.638 32(86.5) 5(13.5) 0.269 34(91.9) 3(8.1)  32(86.5) 5(13.5) 0.342 
 No 1(100.0) 0(0.0)  1(100.0) 0(0.0)  1(100.0) 0(0.0) 0.114 0(0.0) 1(100.0)  
Eye discharge             
 Yes 10(28.6) 25(71.4) 0.625 30(85.7) 5(14.3) 0.852 33(94.3) 2(5.7)  30(85.7) 5(14.3) 0.964 
 No 1(33.3) 2(66.7)  3(100.0) 0(0.0)  2(66.7) 1(33.3) 0.557 2(66.7) 1(33.3)  
Hyperemia             
 Yes 10(27.8) 26(72.2) 0.899 32(88.9) 4(11.1) 0.611 33(91.7) 3(8.3)  31(86.1) 5(13.9) 0.713 
 No 1(50.0) 1(50.0)  1(50.0) 1(50.0)  2(100.0) 0(0.0) 0.357 1(50.0) 1(50.0)  



















Table 5B. Correlating major nasal symptoms with the eye symptoms 
 
 Sleep disturbance Sneezing Nasal itching Nasal discharge 
 Yes No  p value  Yes No p value  Yes No  p value Yes No  p value 
Variable  n (%) n (%)  n (%) n (%)  n (%) n (%)  n (%) n (%)  
Cobblestone-like 
papillae 
            
 Yes 0(0.0) 5(100.0) 0.316 4(80.0) 1(20.0) 0.823 5(100.0) 0(0.0) 0.852 4(80.0) 1(20.0) 0.703 
 No 11(33.3) 22(66.7)  29(87.9) 4(12.1)  30(90.9) 3(9.1)  28(84.8) 5(15.2)  
Cornea abrasion             
 Yes 1(20.0) 4(80.0) 0.956 4(80.0) 1(20.0) 0.823 5(100.0) 0(0.0) 0.852 4(80.0) 1(20.0) 0.703 
 No 10(30.3) 23(69.7)  29(87.9) 4(12.1)  30(90.9) 3(9.1)  28(84.8) 5(15.2)  
VCT             
 Yes 5(25.0) 15(75.0) 0.572 17(85.0) 3(15.0) 0.899 18(90.0) 2(10.0) 0.924 17(85.0) 3(15.0) 0.760 
 No 6(33.3) 12(66.7)  16(88.9) 2(11.1)  17(94.4) 1(5.6)  15(83.3) 3(16.7)  
Mast cell stabilizer             
 Yes 1(14.3) 6(85.7) 0.627 6(85.7) 1(14.3) 0.602 7(100.0) 0(0.0) 0.933 5(71.4) 2(28.6) 0.651 
 No 10(32.3) 21(67.7)  27(87.1) 4(12.9)  28(90.3) 3(9.7)  27(87.1) 4(12.9)  
Steroid             
 Yes 3(37.5) 5(62.5) 0.872 6(75.0) 2(25.0) 0.599 8(100.0) 0(0.0) 0.845 6(75.0) 2(25.0) 0.796 
 No 8(26.7) 22(73.3)  27(90.0) 3(10.0)  27(90.0) 3(10.0)  26(86.7) 4(13.3)  
NB: Chi square test use to determine association as well as Yates corrected Chi square as appropriate 
 
Table 6. Correlating the eye and nasal features with the treatment modalities 
 
 Eye Itching Eye pain Eye redness Eye tearing 
 r  p value r  p value r  p value r  p value 
VCT 0.173 0.298 0.173 0.298 0.173 0.298 0.266 0.106 
Mast cell stabilizer 0.078 0.641 0.078 0.641 0.078 0.641 0.020 0.907 
Steroid 0.085 0.612 0.085 0.612 0.085 0.612 0.484 0.002* 
 Sleep disturbance Sneezing Nasal itching Nasal discharge 
 r  p value r  p value r  p value r  p value 
Anti-histamine 1  1  1  1  
Steroid 0.104 0.533 0.267 0.106 0.187 0.261 0.042 0.803 
Allergen immunotherapy 0.030 0.859 0.120 0.472 0.100 0.549 0.322 0.049* 
Environmental control 0.382 0.018* 0.010 0.952 0.328 0.045* 0.130 0.435 











Previous studies have demonstrated the 
increasing knowledge of the relationship between 
AR and AC. Clinical trials of intranasal therapies 
have proven efficacy in the treatment of AR and 
AC [6]. Majority of the respondents with AR also 
experienced symptoms of AC and other forms of 
allergies. Such clinical correlates include among 
others recurrent itching, redness of the eyes, 
persistent sneezing, runny nose with a positive 
fairly history of allergy. [17] These correlate with 
the findings in our study (Tables 5a,5b and 6). 
However, none of these previous studies were 
available in this study area. This was the reason 




This research was conducted to correlate the 
features of allergic rhinitis with those of 
conjunctivitis and common management and 
preventive measures offered to the patients seen 
in our clinics. The majority of the patients were 
less than 45 years with almost equal sex ratio. 
Eye pain, itching, and redness account for the 
majority of all the eye features, while the 
presence of Cobblestone-like papillae is the least 
eye feature. Nasal itching was the commonest 
nasal symptom and this was seen in the majority 




As per international standard or university 
standard, patient’s consent has been collected 




This was obtained from the Ethical and research 
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